Author

Vaibhav Singh

Institution: Guru Ghasidas Vishwavidyalaya

Observed institution: Guru Ghasidas Vishwavidyalaya

ORCID: 0009-0006-7114-7212

Observed ORCID: 0009-0006-7114-7212

OpenAlex ID: A5028045725

Patent landscape in hydroxamic acid-based HDAC inhibitors (2020–2024): structure–activity relationships and mechanistic insights

2025 · Ekta Shirbhate, Vaibhav Singh, et al. · Expert Opinion on Therapeutic Patents · 4

Heteroaryl-Capped Hydroxamic Acid Derivatives with Varied Linkers: Synthesis and Anticancer Evaluation with Various Apoptosis Analyses in Breast Cancer Cells, Including Docking, Simulation, DFT, and ADMET Studies

2025 · Ekta Shirbhate, Biplob Koch, et al. · Pharmaceuticals · 3

Epigenetic–Genetic Crosstalk at the Cancer–Diabetes Interface: Convergent Molecular Pathways, Multi‐Omics Biomarkers, and Dual Therapeutic Targets

2026 · Vaibhav Singh, Ekta Shirbhate, et al. · The FASEB Journal · 1

Mitochondrial Dynamics and Bioenergetic Reprogramming: Drivers of Cancer Therapy Resistance

2026 · Varsha Johariya, Vaibhav Singh, et al. · Mini-Reviews in Medicinal Chemistry

Targeting Microbiome-Derived Exosomes to Overcome Cancer Therapy Resistance: Mechanisms, Implications, and Opportunities

2025 · Vaibhav Singh, Ekta Shirbhate, et al. · Mini-Reviews in Medicinal Chemistry

Works count: 5

Citation count: 8

H-index: 2

I10-index: